A review and analysis of trials of GLP-1 receptor agonists found that they reduce the risk of cardiovascular and all-cause mortality and stroke
Trends in Pharmacological Science Wong, C.K., & Drucker, D.J
(2024) Bendotti G, Montefusco L, Lunati ME, Usuelli V, Pastore I, Lazzaroni E, et al (2022) The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
In all cases, consult a healthcare professional
Arizona with 0.5 percent of all patients and 2.3 percent of those with obesity, and Colorado with 0.6 percent and 4.1 percent for the same metrics
So when a drug goes under shortage, that essentially gives authority to these compounders to start producing them, you know, to fill in these access gaps